The aim of the study is to evaluate the association of pre-procedural N-terminal pro-B type natriuretic peptide (NT-proBNP) with contrast-induced acute kidney injury (CI-AKI) and long-term outcomes in elderly patients undergoing elective percutaneous coronary intervention (PCI).
C ontrast-induced acute kidney injury (CI-AKI) is a frequent complication in patients undergoing coronary diagnostic and interventional procedures, which increases the risk of dialysis, mortality, length of stay and costs, 1, 2) especially among elderly patients aged ≥ 75 years. 3, 4) However, as there is no effective treatment for CI-AKI, identifying high-risk patients and taking early prophylactic measures are very important.
In most countries, the population of elderly people is growing faster than the overall population.
5) The number of elderly patients who receive percutaneous coronary intervention (PCI) therapy is increasing rapidly due to the development of PCI technology. 6) Elderly patients generally have more comorbidities than younger patients, which increased the risk of mortality and disability. But there is little evidence about elderly patients above 75 years, because most randomized controlled trials (RCTs) have excluded this patient population. Similarly, studies on CI-AKI about elderly patients are also relatively rare.
N-terminal pro-brain natriuretic peptide (NT-proBNP) is a simple but useful biomarker of cardiac and renal function and is associated with short-and long-term outcomes. 7, 8) Some recent studies suggest that NT-proBNP could be useful to predict CI-AKI after coronary angiography(CAG) 9) or PCI, including patients with ST-segmentelevation myocardial infarction(STEMI), 10, 11) acute coronary syndrome(ACS), 12) chronic kidney disease(CKD), 13) and heart failure(HF). 14) However, the relationship between the pre-procedural NT-proBNP and the risk of CI-AKI in elderly patients undergoing elective PCI has not yet been well examined. Therefore, this analysis aimed to identify the association of NT-proBNP with CI-AKI and long-term NT-ProBNP AND CI-AKI mortality in elderly patients undergoing elective PCI.
Methods

Patients:
We conducted a prospective observational study at the Fujian Provincial Hospital, Fujian Cardiovascular Institute, between January 2012 and December 2015. All consecutive elderly patients having age ≥ 75 years and with coronary artery disease (CAD) undergoing elective PCI were enrolled. The exclusion criteria included-(1) ACSs who presented with quite high risk (i.e., admission < 12 hours after ischemic symptoms onset or complicated by cardiogenic shock or acute severe HF in STEMI patients; refractory angina or hemodynamic instability in those with non-ST-elevation acute coronary syndromes (NSTE-ACS)) undergoing primary PCI (pPCI) or emergency PCI (n = 90); (2) end-stage renal disease (estimated glomerular filtration rate [eGFR] < 15 mL/minute/ 1.73 m 2 ) (n = 1); (3) history of radio-contrast agents 48 hours before or 72 hours after the procedure (n = 3); (4) malignant tumor (n = 36); (5) lack of pre-procedural or postprocedural serum creatinine (SCr) (n = 53); (6) Lack of pre-procedural NT-proBNP (n = 13); and (7) administration of NSAIDs, aminoglycosides, cisplatin, or other nephrotoxic drugs 48 hours before and 72 hours after PCI (n = 10). Finally, 540 elderly patients undergoing elective PCI were included in the analysis. The Ethics Committee of the Fujian Provincial Hospital approved the study. Protocol: NT-proBNP was measured using electrochemiluminescence immunoassay (Roche Diagnostics, Germany) at admission (prior to PCI). SCr was measured at admission and daily for the 2 days after contrast exposure. We also measured glucose, blood urea nitrogen (BUN), uric acid (UA), lipid profiles, white blood cell count, platelet and hemoglobin levels, and other standard clinical parameters on the morning of the first or second day after admission. Left ventricular ejection fraction (LVEF) was evaluated in patients using echo-cardiography during hospitalization. Estimated eGFR was evaluated using the level-modified Modification of Diet in Renal Disease equation: 186.3 × serum creatinine -1.154 × (age) -0.203 × 1.212 (if patient was black) × 0.742 (if patient was female). 15) PCI was performed by experienced interventional cardiologists according to standard clinical technique. All patients received nonionic, low-osmolar contrast media (either Iopamiron or Ultravist, both 370 mgI/mL). The use of medications such as antiplatelet agents, β-adrenergic blocking agents, statins, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blocker (ARB), and diuretic drugs was determined by the cardiologists responsible for the patients based on guidelines. Definitions and follow-up: The primary end point was CI-AKI, defined as an absolute SCr increase ≥ 0.3 mg/dL or a relative increase in SCr ≥ 50% within 48 hours of contrast medium exposure. 16) Major adverse clinical events (MACEs) included all-cause mortality, stent restenosis, non-fatal myocardial infarction, and target vessel revascularization. Advanced congestive heart failure (CHF) was a New York Heart Association (NYHA) class > 2 or Killip class > 1. Anemia was defined as hematocrit (HCT) < 0.39 (male) or < 0.36 (female). Peri-hypotension was defined as systolic blood pressure (SBP) < 80 mmHg for at least 1 hour requiring inotropic support with medications or intra-aortic balloon pump (IABP) within 24 hours periprocedurally. 3) All patients included in the study were subject to follow-up by trained nurses using either outpatient clinical visits or telephone contact with the patients or their relatives after discharge. Statistical analysis: All data were analyzed with SPSS software package (version 20.0). Continuous data are described as the mean ± standard deviation or median. Categorical data are expressed as absolute values (percentages). The continuous variables were tested by Student's t-tests or Wilcoxon rank sum test, and categorical variables were tested by χ 2 or Fisher exact test. Receiver operating characteristic (ROC) curve analysis was conducted to determine the best cutoff value of NT-proBNP for detecting CI-AKI using by MedCalc statistical software (MedCalc Software, version 11.4.2.0). Univariate and multivariate logistic regression analyses were used to identify the independent predictors of CI-AKI. Variables that were found to be significant in the univariate analysis (P < 0.05) and a few variables that were confirmed to be significant in clinical practice were included in the multiple logistic regression analysis. The association of NTproBNP with long-term mortality was investigated by Cox regression analysis, and the Kaplan-Meier curve was used to assess the survival time between the CI-AKI group and non-CI-AKI group with a log-rank test, also among 4 groups divided by NT-proBNP quartiles. A value of P < 0.05 was considered statistically significant.
Results
Baseline characteristics and in-hospital mortality:
A total of 540 consecutive elderly patients were enrolled in this study. The mean age was 78.86 ± 3.29 years, and 154 (28.5%) were female, 202 (37.4%) had diabetes, and 423 (78.3%) had hypertension. CI-AKI developed in 54 patients (10%). Table I shows the different baseline clinical characteristics between the patients with CI-AKI and without. Compared with patients without CI-AKI, patients with CI-AKI were older, more likely complicated with CHF, acute myocardial infarction, and perioperative hypotension. Patients with CI-AKI had significantly lower baseline hemoglobin, LVEF, and higher NT-proBNP level than those without CI-AKI. Patients with CI-AKI were also more likely to be treated with diuretics. However, the traditional risk factors of CI-AKI reported by previous studies such as diabetes, anemia, eGFR, and contrast media volume did not differ significantly between the 2 groups.
Compared with patients without CI-AKI, incidence of in-hospital mortality was higher in CI-AKI patients after PCI (5.6% versus 0.4%, P < 0.01; Figure 1 ). Association between NT-proBNP and CI-AKI: According to quartiles of NT-proBNP, higher levels of NTproBNP were related to higher incidence of CI-AKI (4.5% versus 5.2% versus 7.5% versus 22.6%, from Q1 to Q4, respectively, P < 0.0001; Figure 2 ).
The best cutoff value of NT-proBNP for detecting Lin, ET AL CI-AKI was 1133 pg/mL with 66.7% sensitivity and 70.8% specificity according to the ROC analysis (C statistic = 0.719; 95% CI, 0.679-0.756; Figure 3) . By univariate logistic analysis, age, hemoglobin, Lg-NT-proBNP, CHF, AMI, and peri-hypotension were associated with CI-AKI (all P < 0.05), with 3 variables which were confirmed significant in clinical practice such as eGFR < 60 mL/minute/ 
comes:
The median follow-up period was 1.7 years. Cox regression analysis showed that pre-procedural Lg-NTproBNP was an independent risk factor for long-term mortality (adjusted HR = 2.158; 95% CI, 1.246-3.740; P < 0.05) after adjusting for other risk factors including age, SCR > 1.5 mg/dL, CHF, hemoglobin, and perihypotension (Table III) . The Kaplan-Meier curve showed that higher levels of NT-proBNP had the higher all-cause mortality, MACEs and the less survival time according to 4 quartiles of NT-proBNP (both P < 0.001; Figure 4 and 5). Patients with CI-AKI displayed a higher rate of allcause mortality compared with those without (P < 0.0001; Figure 6 ).
Discussion
To our knowledge, this is the first study to demonstrate that pre-procedural NT-proBNP levels are associated with increased risk for CI-AKI and long-term mortality in elderly patients undergoing elective PCI. This study showed that the best cutoff point of pre-procedural NTproBNP for predicting CI-AKI was 1133 pg/mL, which was a strong and independent predictor of CI-AKI, as well as for long-term mortality in elderly patients undergoing elective PCI.
Previous studies suggested that patients ≥75 years had a higher risk of developing CI-AKI, 3, 17, 18) with a metaanalysis reported incidence approximately 16.5%, 19) and were more likely to develop worse prognosis than the general population. In our study, the incidence of CI-AKI was 10%, the main reason for lower incidence than other studies was that the patients undergoing emergency PCI who presented with higher risk of CI-AKI were excluded. Similar to previous studies, patients with CI-AKI in our study had poor long-term outcomes than those without. [20] [21] [22] Guidelines have been suggested that patients undergoing cardiac catheterization with contrast media should receive adequate preparatory hydration. 23) However, as poor vascular condition, it is difficult to achieve adequate hydration in elderly patients, while this population often accompanied by HF, which limits the application of adequate hydration. Meanwhile, it is easy to induce or aggravate the development of HF with adequate hydration in these patients. Therefore, effectively further identifying elderly patients at higher risk for CI-AKI is also important. Several risk factors for the development of CI-AKI in elderly patients undergoing PCI or CAG have been reported, including hypotension, myocardial infarction, emergency PCI, anemia, contrast agent volume > 200 mL, 24) renal insufficiency(eGFR < 60 mL/minute/ 1.73 m 2, 24) or creatinine clearance (CrCl) < 60 mL/minute), 25) CHF 25) or LVEF < 45%, 24) and the use of IABP. 26) However, all the above studies focused on patients aged ≥ 65 years but not ≥ 75 years, who have a higher risk for developing CI-AKI. In our study, NT-proBNP and perihypotension were found to be risk factors of CI-AKI in elderly patients after elective PCI, even after adjusting for other potential confounding factors. BNP or NT-proBNP are easily available biomarkers, which were not only associated with heart and renal failure, but also ACS, atrial fibrillation, anemia, advanced age, and so on. 27 ) BNP or NT-proBNP also had been previously identified as risk factors for CI-AKI in some patients undergoing CAG or PCI. A sub-study of the HORIZONS-AMI trial might be the first to document that after multivariable adjustment for clinical, laboratory, and angiographic variables, BNP remained a significant independent predictor of CI-AKI in patients after pPCI in STEMI. 28) As the longer half-life, NT-proBNP was more stable than BNP and appears more widely used in clinic now. 29) Two recent studies 10, 11) also found that NT-proBNP levels are an independent predictor for CI-AKI in patients after pPCI, furthermore, Liu, et al. 11) showed that the best cutoff point of NT-proBNP for predicting CI-AKI was NT-ProBNP AND CI-AKI 1800 pg/mL, and the predictive value of is similar to the classic Mehran CIN score. In a retrospective study, the authors reported that an NT-proBNP cutoff value of 682 pg/mL predicted CI-AKI with 78% sensitivity and 70% specificity, and was a strong and independent predictor of CI-AKI and long-term mortality. 9) In another study, Liu, et al. 13) demonstrated that the best cutoff value of NTproBNP for detecting CI-AKI in patients with CKD and relative preserved LVEF undergoing PCI was 537 pg/mL, and is also associated with poor clinical outcomes. A recent study by Wang, et al. 14) indicated that in patients with HF and mid-range ejection fraction (HFmrEF), NTproBNP ≥ 3299 pg/mL was associated with CI-AKI and long-term mortality following elective coronary angiogra-Lin, ET AL phy or intervention. According to the results of the above studies, NT-proBNP can be used as an effective biomarker for helping to identify and stratify risk for CI-AKI, and similar to the diagnosis of HF, different subgroups have different optimal NT-proBNP level for identifying of CI-AKI. However, whether NT-proBNP is also an independent risk factor and the best prediction point for CI-AKI in elderly patients after elective PCI is remained unclear. Our findings supplement the prior observations by demonstrated that elevated NT-proBNP was also a powerful predictor for CI-AKI in elderly patients after elective PCI, even after adjusting for potential confounding factors. Meanwhile, a pre-procedural NT-proBNP level > 1133 pg/ mL was found to be a best cutoff point for prediction of CI-AKI, with 66.7% sensitivity and 70.8% specificity, which lower than the optimal cutoff value of NT-proBNP as 1800 pg/mL for diagnosing HF in ≥ 75 patients, but much higher than other patients for predicting CI-AKI except in patients with HF or STEMI had been reported. The reasons of the high cutoff value in elderly patients undergoing elective PCI included following. First, NTproBNP levels increase with age, which was independent of other factors, the age-associated increase in NTproBNP values, maybe due to the change of diastolic dysfunction and response to age-related alterations in cardiac structure or function. 30) Second, NT-proBNP is mainly cleared through renal excretion, and renal dysfunction is more frequently seen in the aged, which leads to higher cutoff points of NT-proBNP in elderly patients.
The mechanisms underlying the association between NT-proBNP and CI-AKI remain uncertain. The potential mechanisms may include the following. First, NT-proBNP is a biomarker reflected the status of increasing left ventricle (LV) wall tension related to volume expansion and pressure overload, 29) which inhibits myocardial contraction, reduces cardiac output, the effect of change may affect hemodynamics, and reduces renal blood flow, further leading to CI-AKI. Second, NT-proBNP also related to other well-recognized risk factors for CI-AKI, such as diabetes mellitus and anemia.
3) However, after adjusting above potential influence factors on NT-proBNP, elevated pre-procedural NT-proBNP levels remained a powerful risk factor of developing CI-AKI, which suggested that additional pathophysiological processes might play a role on NT-proBNP in elderly patients after elective PCI. Previous studies have demonstrated that the levels of serum NT-pro BNP are associated with the severity of CAD, [31] [32] [33] [34] while renal atherosclerosis accompanied by CAD is relatively common among the elderly population. Therefore, elderly patients with severe CAD, even without renal insufficiency, are more likely to have renal atherosclerosis, which appears more susceptible to influence by other factors and cause renal vasoconstriction, decrease of renal blood flow, further inducing medullary hypoxia and ischemia and enhancing the susceptibility to the cytotoxic effects of contrast media. Finally, NT-proBNP is associated with pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6(IL-6), 35) which may also be involved in the process of CI-AKI.
In addition, similar to previous studies, 8, 36, 37) elevated NT-proBNP also was significantly related to long-term mortality in elderly patients, even after adjusting other potential risk factors. Therefore, it may be necessary to measure the NT-proBNP before the procedure in elderly patients for predicting of CI-AKI and poor prognosis. Limitations: We acknowledge several limitations of our study. First, this observational study was conducted at a single-center and included small population, our findings should be confirmed in a large multicenter trial. Second, there were some missing data such as peri-procedural hy-dration volume which the main of prophylactic CI-AKI therapies, which may influence the incidence of CI-AKI. Third, measurements of the peak SCr levels might have been missed because of the variation in the measurement times which may be caused an underestimation of the true incidence of CI-AKI in this population. Finally, we did not analyze the relationship between NT-pro BNP and the degree of coronary atherosclerotic in detail, especially, most patients were not evaluated by ultrasound, computed tomography angiography (CTA), or angiography to evaluate renal artery, we could not understand the real condition of renal atherosclerosis, the relationship between NTpro BNP and atherosclerotic in elderly patients is not clear, which should be evaluated in a future trial.
Conclusions
NT-proBNP is a simple, rapid, and useful laboratory test that should be routinely measured before the procedure to assess the risk of CI-AKI and long-term mortality in elderly patients underwent elective PCI. The cutoff value of pre-procedural NT-proBNP, 1133 pg/mL in our study, may provide guidance for carrying out prevention.
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